Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
Here's Why Shares in PTC Therapeutics Soared This Week
08:35am, Friday, 05'th Sep 2025
Shares in PTC Therapeutics (PTCT 4.43%) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump
10:00am, Thursday, 21'st Aug 2025
PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likel
PTC Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Thursday, 21'st Aug 2025
WARREN, N.J. , Aug. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Cantor Global Healthcare Conference 202
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
03:53pm, Wednesday, 20'th Aug 2025
Company is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 re
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns
11:20am, Tuesday, 19'th Aug 2025
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on Tuesday related to PTC Therapeutics, Inc.‘s PTCT New Drug Application (NDA) for vatiquinone for Friedreich's at
US FDA declines to approve PTC Therapeutics' rare genetic disorder drug
08:06am, Tuesday, 19'th Aug 2025
The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder that causes progressive damage to the nervous system, the company said on Tuesday,
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
08:00am, Tuesday, 19'th Aug 2025
WARREN, N.J. , Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related
PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript
03:19pm, Friday, 08'th Aug 2025
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwe
PTC Therapeutics (PTCT) Reports Q2 Earnings: What Key Metrics Have to Say
07:01pm, Thursday, 07'th Aug 2025
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street
PTCT Earnings Beat but Sales Drop 4%
06:38pm, Thursday, 07'th Aug 2025
PTCT Earnings Beat but Sales Drop 4%
PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates
06:26pm, Thursday, 07'th Aug 2025
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 07'th Aug 2025
– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J. , Aug. 7, 2
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:08am, Thursday, 31'st Jul 2025
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
11:06am, Wednesday, 30'th Jul 2025
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
01:58pm, Tuesday, 29'th Jul 2025
The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.'s PTCT SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).
